These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 27517727)

  • 21. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes.
    Blonde L; Klein EJ; Han J; Zhang B; Mac SM; Poon TH; Taylor KL; Trautmann ME; Kim DD; Kendall DM
    Diabetes Obes Metab; 2006 Jul; 8(4):436-47. PubMed ID: 16776751
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical experience with exenatide in predominantly Asian and Pacific Islander patients with type 2 diabetes.
    Chokrungvaranon N; Chentanez T; Arakaki RF
    Endocrine; 2007 Dec; 32(3):311-6. PubMed ID: 18266113
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Exenatide--an alternative to insulin in the treatment of type 2 diabetes?].
    Kjeldsen R; Sandbaek A
    Ugeskr Laeger; 2008 Sep; 170(39):3039-43. PubMed ID: 18822227
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Liraglutide achieves A1C targets more often than sitagliptin or exenatide when added to metformin in patients with type 2 diabetes and a baseline A1C <8.0%.
    King AB; Montanya E; Pratley RE; Blonde L; Svendsen CB; Donsmark M; Sesti G
    Endocr Pract; 2013; 19(1):64-72. PubMed ID: 23186975
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety of exenatide once weekly in patients with type 2 diabetes mellitus treated with a thiazolidinedione alone or in combination with metformin for 2 years.
    Norwood P; Liutkus JF; Haber H; Pintilei E; Boardman MK; Trautmann ME
    Clin Ther; 2012 Oct; 34(10):2082-90. PubMed ID: 23031623
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial.
    Heine RJ; Van Gaal LF; Johns D; Mihm MJ; Widel MH; Brodows RG;
    Ann Intern Med; 2005 Oct; 143(8):559-69. PubMed ID: 16230722
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).
    Buse JB; Rosenstock J; Sesti G; Schmidt WE; Montanya E; Brett JH; Zychma M; Blonde L;
    Lancet; 2009 Jul; 374(9683):39-47. PubMed ID: 19515413
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A1C and weight outcomes at 18 months in patients with type 2 diabetes treated with exenatide in an ambulatory care setting.
    McAdam-Marx C; Ye X; Brixner DI; Fabunmi R; Wintle M; Boye KS; Misurski D; Nielsen LL
    Diabetes Obes Metab; 2009 Dec; 11(12):1173-4. PubMed ID: 19930007
    [No Abstract]   [Full Text] [Related]  

  • 29. Metabolic effects of the incretin mimetic exenatide in the treatment of type 2 diabetes.
    Schnabel CA; Wintle M; Kolterman O
    Vasc Health Risk Manag; 2006; 2(1):69-77. PubMed ID: 17319471
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Exenatide in combination therapy: small study, big market, and many unanswered questions.
    Malozowski S
    Ann Intern Med; 2007 Apr; 146(7):527-8. PubMed ID: 17404355
    [No Abstract]   [Full Text] [Related]  

  • 31. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial.
    Zinman B; Hoogwerf BJ; Durán García S; Milton DR; Giaconia JM; Kim DD; Trautmann ME; Brodows RG
    Ann Intern Med; 2007 Apr; 146(7):477-85. PubMed ID: 17404349
    [TBL] [Abstract][Full Text] [Related]  

  • 32. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes.
    Blevins T; Pullman J; Malloy J; Yan P; Taylor K; Schulteis C; Trautmann M; Porter L
    J Clin Endocrinol Metab; 2011 May; 96(5):1301-10. PubMed ID: 21307137
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and efficacy of exenatide in combination with insulin in patients with type 2 diabetes mellitus.
    Sheffield CA; Kane MP; Busch RS; Bakst G; Abelseth JM; Hamilton RA
    Endocr Pract; 2008 Apr; 14(3):285-92. PubMed ID: 18463034
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Human islet allotransplantation with Basiliximab in type I diabetic patients with end-stage renal failure.
    Oberholzer J; Toso C; Triponez F; Ris F; Bucher P; Demirag A; Lou J; Majno P; Buehler L; Philippe J; Morel P
    Transplant Proc; 2002 May; 34(3):823-5. PubMed ID: 12034197
    [No Abstract]   [Full Text] [Related]  

  • 35. The effects of exenatide twice daily compared to insulin lispro added to basal insulin in Latin American patients with type 2 diabetes: A retrospective analysis of the 4B trial.
    de Lapertosa SB; Frechtel G; Hardy E; Sauque-Reyna L
    Diabetes Res Clin Pract; 2016 Dec; 122():38-45. PubMed ID: 27776251
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Islet cell transplantation.
    Vaithilingam V; Sundaram G; Tuch BE
    Curr Opin Organ Transplant; 2008 Dec; 13(6):633-8. PubMed ID: 19060555
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical effects of once-weekly exenatide for the treatment of type 2 diabetes mellitus.
    Ryan GJ; Moniri NH; Smiley DD
    Am J Health Syst Pharm; 2013 Jul; 70(13):1123-31. PubMed ID: 23784159
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of exenatide in poorly controlled type 2 diabetes.
    Kaimal N; Schofield J; Zaki A; Patel R; Sharma M; McCourt E; Imtiaz KE
    QJM; 2012 Apr; 105(4):321-6. PubMed ID: 22056400
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of exenatide on measures of diabetic neuropathy in subjects with type 2 diabetes: results from an 18-month proof-of-concept open-label randomized study.
    Jaiswal M; Martin CL; Brown MB; Callaghan B; Albers JW; Feldman EL; Pop-Busui R
    J Diabetes Complications; 2015; 29(8):1287-94. PubMed ID: 26264399
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety profile of exenatide once weekly compared with insulin once daily in Japanese patients with type 2 diabetes treated with oral antidiabetes drug(s): results from a 26-week, randomized, open-label, parallel-group, multicenter, noninferiority study.
    Inagaki N; Atsumi Y; Oura T; Saito H; Imaoka T
    Clin Ther; 2012 Sep; 34(9):1892-908.e1. PubMed ID: 22884767
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.